Evaxion A/S (EVAX) Stock Price, News & Analysis

Company Overview

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes. This approach aims to accelerate candidate discovery, refine antigen selection and enhance the precision of vaccine design. Evaxion’s pipeline encompasses a range of oncology programs targeting solid tumors as well as prophylactic vaccine programs focused on pathogens with high unmet medical need.

Evaxion traces its origins to academic collaborations at the University of Copenhagen and has evolved into a publicly traded company listed on the NASDAQ under the ticker EVAX. The company is led by CEO Thomas Krogh Nielsen, who brings extensive experience in biotech product development and corporate strategy. Under his leadership, Evaxion has entered into research partnerships with academic institutions and industry partners to advance its pipeline through preclinical and early clinical milestones.

Serving a global market, Evaxion collaborates with research centers and biopharma organizations across Europe and North America. Its AI-driven approach is positioned to address challenges in vaccine development by reducing time-to-candidate and improving the likelihood of clinical success. As Evaxion continues to expand its technology platform and advance its pipeline, the company aims to deliver novel immunotherapies and vaccines to patients worldwide.

Key Stats

• Today's Range: $2.86 to $2.99
• 50-Day Range: $2.48 to $3.25
• 52-Week Range: $1.20 to $16.68
• Volume: 12,028 shs
• Average Volume: 879,011 shs
• Market Capitalization: $4.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Evaxion A/S Stock Analysis - MarketRank™

Evaxion A/S scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Evaxion A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Evaxion A/S has a consensus price target of $10.00, representing about 239.0% upside from its current price of $2.95.

Amount of Analyst Coverage

Evaxion A/S has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Evaxion A/S are expected to decrease in the coming year, from ($0.15) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evaxion A/S is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evaxion A/S is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.36% of the float of Evaxion A/S has been sold short.

Short Interest Ratio / Days to Cover

Evaxion A/S has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evaxion A/S has recently decreased by 3.91%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evaxion A/S does not currently pay a dividend.

Dividend Growth

Evaxion A/S does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.36% of the float of Evaxion A/S has been sold short.

Short Interest Ratio / Days to Cover

Evaxion A/S has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evaxion A/S has recently decreased by 3.91%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.32

News Sentiment

Evaxion A/S has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Evaxion A/S this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for EVAX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Evaxion A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evaxion A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.64% of the stock of Evaxion A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.04% of the stock of Evaxion A/S is held by institutions.

EVAX Stock Analysis - Frequently Asked Questions

How have EVAX shares performed this year?

Evaxion A/S's stock was trading at $4.2270 at the start of the year. Since then, EVAX shares have decreased by 30.2% and is now trading at $2.95.

How were Evaxion A/S's earnings last quarter?

Evaxion A/S - Sponsored ADR (NASDAQ:EVAX) announced its earnings results on Thursday, August, 14th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.26. The business had revenue of $0.04 million for the quarter. Evaxion A/S had a negative trailing twelve-month return on equity of 319.52% and a negative net margin of 316.03%.
Read the conference call transcript.

When did Evaxion A/S's stock split?

Evaxion A/S's stock reverse split on Monday, January 13th 2025.The 1-5 reverse split was announced on Monday, December 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

When did Evaxion A/S IPO?

Evaxion A/S (EVAX) raised $31 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 2,800,000 shares at $10.00-$12.00 per share. Oppenheimer & Co. served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

How do I buy shares of Evaxion A/S?

Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evaxion A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evaxion A/S investors own include PayPal (PYPL), Arista Networks (ANET), Tesla (TSLA), ChargePoint (CHPT), MercadoLibre (MELI), ASML (ASML).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVAX
• CIK: 1828253
• Web: www.evaxion-biotech.com
• Phone: 45-5353-1850
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Evaxion A/S: $10.00
• High Price Target: $14.00
• Low Price Target: $6.00
• Potential Upside/Downside: +239.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.57 million
• Net Margins: -316.03%
• Pretax Margin: -400.88%
• Return on Equity: -319.52%
• Return on Assets: -63.56%

Debt

• Debt-to-Equity Ratio: 1.73
• Current Ratio: 3.42
• Quick Ratio: 3.42

Sales & Book Value

• Annual Sales: $3.34 million
• Price / Sales: 1.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.18) per share
• Price / Book: -2.50

Miscellaneous

• Outstanding Shares: 1,400,000
• Free Float: 819,000
• Market Cap: $4.12 million
• Optionable: No Data
• Beta: 0.14